Influenza Vaccines Market in Top 5 European Countries to 2022 - Market Size, Development and Forecasts
Influenza Vaccine Market is expected to reach more than US$ 1 Billion across the 5 major markets (5MM) of the France, Germany, Italy, Spain and United Kingdom by the year end of 2022.
Market growth can be attributed to factors such as increased disease awareness, expanded recommendations by governmental and advisory bodies to be vaccinated against Influenza, introduction of quadrivalent influenza vaccines, increase in the size of the elderly population in most countries.
United Kingdom influenza vaccine market is the most attractive of those covered in the report. The United Kingdom market for influenza vaccine is expected to grow at a CAGR of XX% and is expected to reach at US$ XXX Million by the end of the forecasted period. Germany will be the second–largest market for influenza vaccine which is expected to grow at a CAGR of XX% by 2022. France is expected to be third largest influenza vaccine market being followed by Italy by the end of the forecasted period.
Further, prudent analysis has been done on the competitor’s part, where three major players grab major share of the influenza vaccine market by revenue. Sanofi Pasteur, GlaxoSmithKline(GSK), Seqirus, AstraZeneca and Protein Sciences Corporation are the key influencers with their products in the influenza vaccine market. Other emerging players such as Novavax, Daiichi–Sankyo, Mitsubishi Tanabe Pharma, BiondVax Pharmaceuticals Ltd, and VaxInnate are making novel technology based influenza vaccine which is likely to affect the market share during the forecast period.
The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry–validated market data. It also contains projection using a suitable set of assumptions and methodologies. It provides essential insights into influenza vaccine sales forecast for the top five countries, comprising the UK, France, Italy, Spain and Germany until 2022. It also covers vaccination patterns and geographic distribution and offers a clear view of the regulatory landscape. Additionally, the report includes assessment of clinical trials, pipeline and promising vaccines in influenza vaccine market. Key trends in terms of M&A, collaborations and licensing agreements are analyzed with details. The report concludes with the profiles of major players in the influenza vaccine market, such as Sanofi Pasteur, GSK, Sequirus, AstraZenecca and Protein Sciences Corporation. The major market players are evaluated on various parameters such as company overview, product outlook and sales analysis of influenza vaccine market from 2011 to 2022. The report also entails major drivers and barriers of influenza vaccine market.
Five Major European Markets(5MM) covered in the report are as follows:
1. United Kingdom
2. France
3. Italy
4. Spain
5. Germany
Major and Promising Vaccines covered in the report are as follows:
1. Fluzone High–Dose
2. Fluzone Quadrivalent
3. Intradermal (ID) Trivalent
4. Vaxigrip
5. Fluarix Quadrivalent
6. Flulaval Quadrivalent
7. Fluenz Tetra
8. FluMist Quadrivalent
9. Flublok
10. VN–100
11. M–001
12. VAX–2012Q
13. TAK – 850
14. Flucelvax Quadrivalent
15. Afluria Quadrivalent
16. Agrippal
17. Fluad
18. Fluvirin
19. Fluvax
Key Companies Covered in the Report are as follows:
1. Sanofi Pasteur
2. GlaxoSmithKline(GSK)
3. Seqirus
4. AstraZenecca
5. Protein Sciences Corporation
6. Novavax
7. Daiichi–Sankyo
8. Mitsubishi Tanabe Pharma
9. BiondVax Pharmaceuticals Ltd
10. VaxInnate
Market growth can be attributed to factors such as increased disease awareness, expanded recommendations by governmental and advisory bodies to be vaccinated against Influenza, introduction of quadrivalent influenza vaccines, increase in the size of the elderly population in most countries.
United Kingdom influenza vaccine market is the most attractive of those covered in the report. The United Kingdom market for influenza vaccine is expected to grow at a CAGR of XX% and is expected to reach at US$ XXX Million by the end of the forecasted period. Germany will be the second–largest market for influenza vaccine which is expected to grow at a CAGR of XX% by 2022. France is expected to be third largest influenza vaccine market being followed by Italy by the end of the forecasted period.
Further, prudent analysis has been done on the competitor’s part, where three major players grab major share of the influenza vaccine market by revenue. Sanofi Pasteur, GlaxoSmithKline(GSK), Seqirus, AstraZeneca and Protein Sciences Corporation are the key influencers with their products in the influenza vaccine market. Other emerging players such as Novavax, Daiichi–Sankyo, Mitsubishi Tanabe Pharma, BiondVax Pharmaceuticals Ltd, and VaxInnate are making novel technology based influenza vaccine which is likely to affect the market share during the forecast period.
The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry–validated market data. It also contains projection using a suitable set of assumptions and methodologies. It provides essential insights into influenza vaccine sales forecast for the top five countries, comprising the UK, France, Italy, Spain and Germany until 2022. It also covers vaccination patterns and geographic distribution and offers a clear view of the regulatory landscape. Additionally, the report includes assessment of clinical trials, pipeline and promising vaccines in influenza vaccine market. Key trends in terms of M&A, collaborations and licensing agreements are analyzed with details. The report concludes with the profiles of major players in the influenza vaccine market, such as Sanofi Pasteur, GSK, Sequirus, AstraZenecca and Protein Sciences Corporation. The major market players are evaluated on various parameters such as company overview, product outlook and sales analysis of influenza vaccine market from 2011 to 2022. The report also entails major drivers and barriers of influenza vaccine market.
Five Major European Markets(5MM) covered in the report are as follows:
1. United Kingdom
2. France
3. Italy
4. Spain
5. Germany
Major and Promising Vaccines covered in the report are as follows:
1. Fluzone High–Dose
2. Fluzone Quadrivalent
3. Intradermal (ID) Trivalent
4. Vaxigrip
5. Fluarix Quadrivalent
6. Flulaval Quadrivalent
7. Fluenz Tetra
8. FluMist Quadrivalent
9. Flublok
10. VN–100
11. M–001
12. VAX–2012Q
13. TAK – 850
14. Flucelvax Quadrivalent
15. Afluria Quadrivalent
16. Agrippal
17. Fluad
18. Fluvirin
19. Fluvax
Key Companies Covered in the Report are as follows:
1. Sanofi Pasteur
2. GlaxoSmithKline(GSK)
3. Seqirus
4. AstraZenecca
5. Protein Sciences Corporation
6. Novavax
7. Daiichi–Sankyo
8. Mitsubishi Tanabe Pharma
9. BiondVax Pharmaceuticals Ltd
10. VaxInnate
1. EXECUTIVE SUMMARY
2. INFLUENZA VACCINE MARKET IN TOP 5 EUROPEAN COUNTRIES – MARKET OVERVIEW
2.1 Influenza Vaccine Market
2.2 Number of Persons Vaccinated with Influenza Vaccine
2.3 Influenza Vaccine Market Share
2.4 Persons Being Vaccinated with Influenza Vaccine Share
3. INFLUENZA VACCINE MARKET DRIVERS AND BARRIERS
3.1 Market Drivers
3.2 Market Barriers
4. INFLUENZA VACCINE MARKET IN TOP 5 EUROPEAN COUNTRIES – GEOGRAPHICAL LANDSCAPE
4.1 Germany
4.1.1 Influenza Vaccine Market
4.1.2 Total – Number of Persons Vaccinated with Influenza Vaccine
4.1.2.1 Number of 60+ Years of Age Persons Vaccinated
4.1.2.2 Number of Pregnant Women Vaccinated
4.1.2.3 Number of Chronic Medical Condition Persons Vaccinated
4.1.2.4 Number of Healthcare Workers Vaccinated
4.2 France
4.2.1 Influenza Vaccine Market
4.2.2 Total – Number of Persons Vaccinated with Influenza Vaccine
4.2.2.1 Number of 65+ Years of Age Persons Vaccinated
4.2.2.2 Number of Pregnant Women Vaccinated
4.2.2.3 Number of Chronic Medical Condition Persons Vaccinated
4.2.2.4 Number of Healthcare Workers Vaccinated
4.3 Italy
4.3.1 Influenza Vaccine Market
4.3.2 Total – Number of Persons Vaccinated with Influenza Vaccine
4.3.2.1 Number of 65+ Years of Age Persons Vaccinated
4.3.2.2 Number of Pregnant Women Vaccinated
4.3.2.3 Number of Chronic Medical Condition Persons Vaccinated
4.3.2.4 Number of Healthcare Workers Vaccinated
4.4 United Kingdom
4.4.1 Influenza Vaccine Market
4.4.2 Total – Number of Persons Vaccinated with Influenza Vaccine
4.4.2.1 Number of Children Vaccinated
4.4.2.2 Number of 65+ Years of Age Persons Vaccinated
4.4.2.3 Number of Pregnant Women Vaccinated
4.4.2.4 Number of Chronic Medical Condition Persons Vaccinated
4.4.2.5 Number of Healthcare Workers Vaccinated
4.5 Spain
4.5.1 Influenza Vaccine Market
4.5.2 Total – Number of Persons Vaccinated with Influenza Vaccine
4.5.2.1 Number of 65+ Years of Age Persons Vaccinated
4.5.2.2 Number of Pregnant Women Vaccinated
4.5.2.3 Number of Chronic Medical Condition Persons Vaccinated
4.5.2.4 Number of Healthcare Workers Vaccinated
5. EUROPEAN UNION INFLUENZA VACCINE MARKET – REGULATORY LANDSCAPE
6. MARKET DYNAMICS – MERGERS, ACQUISITIONS, KEY AGREEMENTS & COLLABORATIONS
6.1 Merger & Acquisitions
6.2 Collaboration Deal
6.3 Licensing, Exclusive & Distribution Agreement Deal
6.3.1 Licensing Agreement
6.3.2 Exclusive Agreement
6.3.3 Distribution Agreement
7. INFLUENZA VACCINE – PIPELINE ASSESSMENT
7.1 Promising Vaccine in Clinical Development
7.2 Promising Vaccine in Early–Stage Development
8. INFLUENZA VACCINE – CLINICAL TRIALS ASSESSMENT BY PHASE AND TRIAL STATUS
8.1 Year 2016
8.2 Year 2015
8.3 Year 2014
8.4 Year 2013
9. KEY COMPANIES ANALYSIS
9.1 Sanofi Pasteur
9.1.1 Business Overview
9.1.2 Sanofi Pasteur – Influenza Vaccine Outlook
9.1.2.1 Fluzone High–Dose Vaccine
9.1.2.2 Fluzone Quadrivalent Vaccine
9.1.2.3 Intradermal (ID) Trivalent Influenza Vaccine
9.1.2.4 Vaxigrip Vaccine
9.1.3 Influenza Vaccine Sales Analysis
9.2 GlaxoSmithKline (GSK)
9.2.1 GlaxoSmithKline(GSK) – Influenza Vaccine Outlook
9.2.1.1 Fluarix Quadrivalent
9.2.1.2 Flulaval Quadrivalent
9.2.2 Influenza Vaccine Sales Analysis & Forecast
9.3 AstraZeneca
9.3.1 Business Overview
9.3.2 AstraZeneca – Influenza Vaccine Outlook
9.3.2.1 Fluenz Tetra/FluMist Quadrivalent
9.3.3 Influenza Vaccine Sales Analysis
9.4 Protein Sciences Corporation
9.4.1 Business Overview
9.4.2 Protein Sciences Corporation – Influenza Vaccine Outlook
9.4.2.1 Flublok
9.5 Seqirus (CSL Limited)
9.5.1 Business Overview
9.5.2 Seqirus – Influenza Vaccine Outlook
9.5.2.1 Flucelvax Quadrivalent
9.5.2.2 Afluria Quadrivalent
9.5.2.3 Agrippal
9.5.2.4 Fluad
9.5.2.5 Fluvirin
9.5.2.6 Fluvax
2. INFLUENZA VACCINE MARKET IN TOP 5 EUROPEAN COUNTRIES – MARKET OVERVIEW
2.1 Influenza Vaccine Market
2.2 Number of Persons Vaccinated with Influenza Vaccine
2.3 Influenza Vaccine Market Share
2.4 Persons Being Vaccinated with Influenza Vaccine Share
3. INFLUENZA VACCINE MARKET DRIVERS AND BARRIERS
3.1 Market Drivers
3.2 Market Barriers
4. INFLUENZA VACCINE MARKET IN TOP 5 EUROPEAN COUNTRIES – GEOGRAPHICAL LANDSCAPE
4.1 Germany
4.1.1 Influenza Vaccine Market
4.1.2 Total – Number of Persons Vaccinated with Influenza Vaccine
4.1.2.1 Number of 60+ Years of Age Persons Vaccinated
4.1.2.2 Number of Pregnant Women Vaccinated
4.1.2.3 Number of Chronic Medical Condition Persons Vaccinated
4.1.2.4 Number of Healthcare Workers Vaccinated
4.2 France
4.2.1 Influenza Vaccine Market
4.2.2 Total – Number of Persons Vaccinated with Influenza Vaccine
4.2.2.1 Number of 65+ Years of Age Persons Vaccinated
4.2.2.2 Number of Pregnant Women Vaccinated
4.2.2.3 Number of Chronic Medical Condition Persons Vaccinated
4.2.2.4 Number of Healthcare Workers Vaccinated
4.3 Italy
4.3.1 Influenza Vaccine Market
4.3.2 Total – Number of Persons Vaccinated with Influenza Vaccine
4.3.2.1 Number of 65+ Years of Age Persons Vaccinated
4.3.2.2 Number of Pregnant Women Vaccinated
4.3.2.3 Number of Chronic Medical Condition Persons Vaccinated
4.3.2.4 Number of Healthcare Workers Vaccinated
4.4 United Kingdom
4.4.1 Influenza Vaccine Market
4.4.2 Total – Number of Persons Vaccinated with Influenza Vaccine
4.4.2.1 Number of Children Vaccinated
4.4.2.2 Number of 65+ Years of Age Persons Vaccinated
4.4.2.3 Number of Pregnant Women Vaccinated
4.4.2.4 Number of Chronic Medical Condition Persons Vaccinated
4.4.2.5 Number of Healthcare Workers Vaccinated
4.5 Spain
4.5.1 Influenza Vaccine Market
4.5.2 Total – Number of Persons Vaccinated with Influenza Vaccine
4.5.2.1 Number of 65+ Years of Age Persons Vaccinated
4.5.2.2 Number of Pregnant Women Vaccinated
4.5.2.3 Number of Chronic Medical Condition Persons Vaccinated
4.5.2.4 Number of Healthcare Workers Vaccinated
5. EUROPEAN UNION INFLUENZA VACCINE MARKET – REGULATORY LANDSCAPE
6. MARKET DYNAMICS – MERGERS, ACQUISITIONS, KEY AGREEMENTS & COLLABORATIONS
6.1 Merger & Acquisitions
6.2 Collaboration Deal
6.3 Licensing, Exclusive & Distribution Agreement Deal
6.3.1 Licensing Agreement
6.3.2 Exclusive Agreement
6.3.3 Distribution Agreement
7. INFLUENZA VACCINE – PIPELINE ASSESSMENT
7.1 Promising Vaccine in Clinical Development
7.2 Promising Vaccine in Early–Stage Development
8. INFLUENZA VACCINE – CLINICAL TRIALS ASSESSMENT BY PHASE AND TRIAL STATUS
8.1 Year 2016
8.2 Year 2015
8.3 Year 2014
8.4 Year 2013
9. KEY COMPANIES ANALYSIS
9.1 Sanofi Pasteur
9.1.1 Business Overview
9.1.2 Sanofi Pasteur – Influenza Vaccine Outlook
9.1.2.1 Fluzone High–Dose Vaccine
9.1.2.2 Fluzone Quadrivalent Vaccine
9.1.2.3 Intradermal (ID) Trivalent Influenza Vaccine
9.1.2.4 Vaxigrip Vaccine
9.1.3 Influenza Vaccine Sales Analysis
9.2 GlaxoSmithKline (GSK)
9.2.1 GlaxoSmithKline(GSK) – Influenza Vaccine Outlook
9.2.1.1 Fluarix Quadrivalent
9.2.1.2 Flulaval Quadrivalent
9.2.2 Influenza Vaccine Sales Analysis & Forecast
9.3 AstraZeneca
9.3.1 Business Overview
9.3.2 AstraZeneca – Influenza Vaccine Outlook
9.3.2.1 Fluenz Tetra/FluMist Quadrivalent
9.3.3 Influenza Vaccine Sales Analysis
9.4 Protein Sciences Corporation
9.4.1 Business Overview
9.4.2 Protein Sciences Corporation – Influenza Vaccine Outlook
9.4.2.1 Flublok
9.5 Seqirus (CSL Limited)
9.5.1 Business Overview
9.5.2 Seqirus – Influenza Vaccine Outlook
9.5.2.1 Flucelvax Quadrivalent
9.5.2.2 Afluria Quadrivalent
9.5.2.3 Agrippal
9.5.2.4 Fluad
9.5.2.5 Fluvirin
9.5.2.6 Fluvax
LIST OF TABLES
Table 2 1:Top 5 Countries – Influenza Vaccine Market Share (Percent),2010 – 2015
Table 2 2: Top 5 Countries – Forecast for Influenza Vaccine Market Share (Percent),2016 – 2022
Table 2 3: Top Seven Countries – Number of Persons Vaccinated with Influenza Vaccine Share(Percent),2010 – 2015
Table 2 4: Top Seven Countries – Forecast for Number of Persons Vaccinated with Influenza Vaccine Share(Percent),2016 – 2022
Table 5 1: European Union – Simplified Regulatory Pathway from Preclinical to the Marketing Authorization
Table 6 1: Influenza Vaccine Market – Merger & Acquisitions (Million US$),2003 – 2015
Table 6 2: Influenza Vaccine Market – Collaborations Deal,2007 – 2016
Table 6 3: Influenza Vaccine Market – Licensing Agreement,2007 – 2016
Table 6 4: Influenza Vaccine Market – Exclusive Agreement,2009 – 2016
Table 6 5: Influenza Vaccine Market – Distribution Agreement,2005 – 2016
Table 2 1:Top 5 Countries – Influenza Vaccine Market Share (Percent),2010 – 2015
Table 2 2: Top 5 Countries – Forecast for Influenza Vaccine Market Share (Percent),2016 – 2022
Table 2 3: Top Seven Countries – Number of Persons Vaccinated with Influenza Vaccine Share(Percent),2010 – 2015
Table 2 4: Top Seven Countries – Forecast for Number of Persons Vaccinated with Influenza Vaccine Share(Percent),2016 – 2022
Table 5 1: European Union – Simplified Regulatory Pathway from Preclinical to the Marketing Authorization
Table 6 1: Influenza Vaccine Market – Merger & Acquisitions (Million US$),2003 – 2015
Table 6 2: Influenza Vaccine Market – Collaborations Deal,2007 – 2016
Table 6 3: Influenza Vaccine Market – Licensing Agreement,2007 – 2016
Table 6 4: Influenza Vaccine Market – Exclusive Agreement,2009 – 2016
Table 6 5: Influenza Vaccine Market – Distribution Agreement,2005 – 2016
LIST OF FIGURES
Figure 2–1: Top 5 Countries – Influenza Vaccine Market (Million US$),2010 – 2015
Figure 2–2: Top 5 Countries – Forecast for Influenza Vaccine Market (Million US$),2016 – 2022
Figure 2–3: Top 5 Countries – Number of Persons Vaccinated with Influenza Vaccine(Million),2010 – 2015
Figure 2–4: Top 5 Countries – Forecast for Number of Persons Vaccinated with Influenza Vaccine(Million),2016 – 2022
Figure 4–9: Germany – Influenza Vaccine Market (Million US$),2010 – 2015
Figure 4–10: Germany – Forecast for Influenza Vaccine Market (Million US$),2016 – 2022
Figure 4–11: Germany – Total Number of Persons Vaccinated(Thousand), 2010 – 2015
Figure 4–12: Germany – Forecast for Total Number of Persons Vaccinated(Thousand), 2016 – 2022
Figure 4–13: Germany – Number of 60+ Years of Age Persons Vaccinated(Thousand),2010 – 2015
Figure 4–14: Germany – Forecast for Number of 60+ Years of Age Persons Vaccinated(Thousand),2016 – 2022
Figure 4–15: Germany – Number of Pregnant Women Vaccinated(Thousand),2010 – 2015
Figure 4–16: Germany – Forecast for Number of Pregnant Women Vaccinated(Thousand),2016 – 2022
Figure 4–17: Germany – Number of Chronic Medical Condition Persons Vaccinated(Thousand),2010 – 2015
Figure 4–18: Germany – Forecast for Number of Chronic Medical Condition Persons Vaccinated(Thousand),2016 – 2022
Figure 4–19: Germany – Number of Healthcare Workers Vaccinated(Thousand),2010 – 2015
Figure 4–20: Germany – Forecast for Number of Healthcare Workers Vaccinated(Thousand),2016 – 2022
Figure 4–21: France – Influenza Vaccine Market (Million US$),2010 – 2015
Figure 4–22: France – Forecast for Influenza Vaccine Market (Million US$),2016 – 2022
Figure 4–23: France – Total Number of Persons Vaccinated(Thousand), 2010 – 2015
Figure 4–24: France – Forecast for Total Number of Persons Vaccinated(Thousand), 2016 – 2022
Figure 4–25: France – Number of 65+ Years of Age Persons Vaccinated(Thousand),2010 – 2015
Figure 4–26: France – Forecast for Number of 60+ Years of Age Persons Vaccinated(Thousand),2016 – 2022
Figure 4–27: France – Number of Pregnant Women Vaccinated(Thousand),2010 – 2015
Figure 4–28: France – Forecast for Number of Pregnant Women Vaccinated(Thousand),2016 – 2022
Figure 4–29: France – Number of Chronic Medical Condition Persons Vaccinated(Thousand),2010 – 2015
Figure 4–30: France – Forecast for Number of Chronic Medical Condition Persons Vaccinated(Thousand),2016 – 2022
Figure 4–31: France – Number of Healthcare Workers Vaccinated(Thousand),2010 – 2015
Figure 4–32: France – Forecast for Number of Healthcare Workers Vaccinated(Thousand),2016 – 2022
Figure 4–33: Italy – Influenza Vaccine Market (Million US$),2010 – 2015
Figure 4–34: Italy – Forecast for Influenza Vaccine Market (Million US$),2016 – 2022
Figure 4–35: Italy – Total Number of Persons Vaccinated(Thousand), 2010 – 2015
Figure 4–36: Italy – Forecast for Total Number of Persons Vaccinated(Thousand), 2016 – 2022
Figure 4–37: Italy – Number of 65+ Years of Age Persons Vaccinated(Thousand),2010 – 2015
Figure 4–38: Italy – Forecast for Number of 65+ Years of Age Persons Vaccinated(Thousand),2016 – 2022
Figure 4–39: Italy – Number of Pregnant Women Vaccinated(Thousand),2010 – 2015
Figure 4–40: Italy – Forecast for Number of Pregnant Women Vaccinated(Thousand),2016 – 2022
Figure 4–41: Italy – Number of Chronic Medical Condition Persons Vaccinated(Thousand),2010 – 2015
Figure 4–42: Italy – Forecast for Number of Chronic Medical Condition Persons Vaccinated(Thousand),2016 – 2022
Figure 4–43: Italy – Number of Healthcare Workers Vaccinated(Thousand),2010 – 2015
Figure 4–44: Italy – Forecast for Number of Healthcare Workers Vaccinated(Thousand),2016 – 2022
Figure 4–45: United Kingdom – Influenza Vaccine Market (Million US$),2010 – 2015
Figure 4–46: United Kingdom – Forecast for Influenza Vaccine Market (Million US$),2016 – 2022
Figure 4–47: United Kingdom – Total Number of Persons Vaccinated(Thousand), 2010 – 2015
Figure 4–48: United Kingdom – Forecast for Total Number of Persons Vaccinated(Thousand), 2016 – 2022
Figure 4–49: United Kingdom – Vaccination Coverage Rate (%)
Figure 4–50: United Kingdom – Number of Children Vaccinated(Thousand),2013 – 2015
Figure 4–51: United Kingdom – Forecast for Number of Children Vaccinated(Thousand),2016 – 2022
Figure 4–52: United Kingdom – Number of 65+ Years of Age Persons Vaccinated(Thousand),2010 – 2015
Figure 4–53: United Kingdom – Forecast for Number of 65+ Years of Age Persons Vaccinated(Thousand),2016 – 2022
Figure 4–54: United Kingdom – Number of Pregnant Women Vaccinated(Thousand),2010 – 2015
Figure 4–55: United Kingdom – Forecast for Number of Pregnant Women Vaccinated(Thousand),2016 – 2022
Figure 4–56: United Kingdom – Number of Chronic Medical Condition Persons Vaccinated(Thousand),2010 – 2015
Figure 4–57: United Kingdom – Forecast for Number of Chronic Medical Condition Persons Vaccinated(Thousand),2016 – 2022
Figure 4–58: United Kingdom – Number of Healthcare Workers Vaccinated(Thousand),2010 – 2015
Figure 4–59: United Kingdom – Forecast for Number of Healthcare Workers Vaccinated(Thousand),2016 – 2022
Figure 4–60: Spain – Influenza Vaccine Market (Million US$),2010 – 2015
Figure 4–61: Spain – Forecast for Influenza Vaccine Market (Million US$),2016 – 2022
Figure 4–62: Spain – Total Number of Persons Vaccinated(Thousand), 2010 – 2015
Figure 4–63: Spain – Forecast for Total Number of Persons Vaccinated(Thousand), 2016 – 2022
Figure 4–64: Spain – Number of 65+ Years of Age Persons Vaccinated(Thousand),2010 – 2015
Figure 4–65: Spain – Forecast for Number of 65+ Years of Age Persons Vaccinated(Thousand),2016 – 2022
Figure 4–66: Spain – Number of Pregnant Women Vaccinated(Thousand),2010 – 2015
Figure 4–67: Spain – Forecast for Number of Pregnant Women Vaccinated(Thousand),2016 – 2022
Figure 4–68: Spain – Number of Chronic Medical Condition Persons Vaccinated(Thousand),2010 – 2015
Figure 4–69: Spain – Forecast for Number of Chronic Medical Condition Persons Vaccinated(Thousand),2016 – 2022
Figure 4–70: Spain – Number of Healthcare Workers Vaccinated(Thousand),2010 – 2015
Figure 4–71: Spain – Forecast for Number of Healthcare Workers Vaccinated(Thousand),2016 – 2022
Figure 10–1: Sanofi Pasteur – Influenza Vaccine Net Sales (Million US$),2011 – 2015
Figure 10–2: Sanofi Pasteur – Forecast for Influenza Vaccine Net Sales (Million US$),2016 – 2022
Figure 10–3: GSK – Influenza Vaccine Net Sales (Million US$),2011 – 2015
Figure 10–4: GSK – Forecast for Influenza Vaccine Net Sales (Million US$),2016 – 2022
Figure 10–5: AstraZeneca – Influenza Vaccine Net Sales (Million US$),2011 – 2015
Figure 2–1: Top 5 Countries – Influenza Vaccine Market (Million US$),2010 – 2015
Figure 2–2: Top 5 Countries – Forecast for Influenza Vaccine Market (Million US$),2016 – 2022
Figure 2–3: Top 5 Countries – Number of Persons Vaccinated with Influenza Vaccine(Million),2010 – 2015
Figure 2–4: Top 5 Countries – Forecast for Number of Persons Vaccinated with Influenza Vaccine(Million),2016 – 2022
Figure 4–9: Germany – Influenza Vaccine Market (Million US$),2010 – 2015
Figure 4–10: Germany – Forecast for Influenza Vaccine Market (Million US$),2016 – 2022
Figure 4–11: Germany – Total Number of Persons Vaccinated(Thousand), 2010 – 2015
Figure 4–12: Germany – Forecast for Total Number of Persons Vaccinated(Thousand), 2016 – 2022
Figure 4–13: Germany – Number of 60+ Years of Age Persons Vaccinated(Thousand),2010 – 2015
Figure 4–14: Germany – Forecast for Number of 60+ Years of Age Persons Vaccinated(Thousand),2016 – 2022
Figure 4–15: Germany – Number of Pregnant Women Vaccinated(Thousand),2010 – 2015
Figure 4–16: Germany – Forecast for Number of Pregnant Women Vaccinated(Thousand),2016 – 2022
Figure 4–17: Germany – Number of Chronic Medical Condition Persons Vaccinated(Thousand),2010 – 2015
Figure 4–18: Germany – Forecast for Number of Chronic Medical Condition Persons Vaccinated(Thousand),2016 – 2022
Figure 4–19: Germany – Number of Healthcare Workers Vaccinated(Thousand),2010 – 2015
Figure 4–20: Germany – Forecast for Number of Healthcare Workers Vaccinated(Thousand),2016 – 2022
Figure 4–21: France – Influenza Vaccine Market (Million US$),2010 – 2015
Figure 4–22: France – Forecast for Influenza Vaccine Market (Million US$),2016 – 2022
Figure 4–23: France – Total Number of Persons Vaccinated(Thousand), 2010 – 2015
Figure 4–24: France – Forecast for Total Number of Persons Vaccinated(Thousand), 2016 – 2022
Figure 4–25: France – Number of 65+ Years of Age Persons Vaccinated(Thousand),2010 – 2015
Figure 4–26: France – Forecast for Number of 60+ Years of Age Persons Vaccinated(Thousand),2016 – 2022
Figure 4–27: France – Number of Pregnant Women Vaccinated(Thousand),2010 – 2015
Figure 4–28: France – Forecast for Number of Pregnant Women Vaccinated(Thousand),2016 – 2022
Figure 4–29: France – Number of Chronic Medical Condition Persons Vaccinated(Thousand),2010 – 2015
Figure 4–30: France – Forecast for Number of Chronic Medical Condition Persons Vaccinated(Thousand),2016 – 2022
Figure 4–31: France – Number of Healthcare Workers Vaccinated(Thousand),2010 – 2015
Figure 4–32: France – Forecast for Number of Healthcare Workers Vaccinated(Thousand),2016 – 2022
Figure 4–33: Italy – Influenza Vaccine Market (Million US$),2010 – 2015
Figure 4–34: Italy – Forecast for Influenza Vaccine Market (Million US$),2016 – 2022
Figure 4–35: Italy – Total Number of Persons Vaccinated(Thousand), 2010 – 2015
Figure 4–36: Italy – Forecast for Total Number of Persons Vaccinated(Thousand), 2016 – 2022
Figure 4–37: Italy – Number of 65+ Years of Age Persons Vaccinated(Thousand),2010 – 2015
Figure 4–38: Italy – Forecast for Number of 65+ Years of Age Persons Vaccinated(Thousand),2016 – 2022
Figure 4–39: Italy – Number of Pregnant Women Vaccinated(Thousand),2010 – 2015
Figure 4–40: Italy – Forecast for Number of Pregnant Women Vaccinated(Thousand),2016 – 2022
Figure 4–41: Italy – Number of Chronic Medical Condition Persons Vaccinated(Thousand),2010 – 2015
Figure 4–42: Italy – Forecast for Number of Chronic Medical Condition Persons Vaccinated(Thousand),2016 – 2022
Figure 4–43: Italy – Number of Healthcare Workers Vaccinated(Thousand),2010 – 2015
Figure 4–44: Italy – Forecast for Number of Healthcare Workers Vaccinated(Thousand),2016 – 2022
Figure 4–45: United Kingdom – Influenza Vaccine Market (Million US$),2010 – 2015
Figure 4–46: United Kingdom – Forecast for Influenza Vaccine Market (Million US$),2016 – 2022
Figure 4–47: United Kingdom – Total Number of Persons Vaccinated(Thousand), 2010 – 2015
Figure 4–48: United Kingdom – Forecast for Total Number of Persons Vaccinated(Thousand), 2016 – 2022
Figure 4–49: United Kingdom – Vaccination Coverage Rate (%)
Figure 4–50: United Kingdom – Number of Children Vaccinated(Thousand),2013 – 2015
Figure 4–51: United Kingdom – Forecast for Number of Children Vaccinated(Thousand),2016 – 2022
Figure 4–52: United Kingdom – Number of 65+ Years of Age Persons Vaccinated(Thousand),2010 – 2015
Figure 4–53: United Kingdom – Forecast for Number of 65+ Years of Age Persons Vaccinated(Thousand),2016 – 2022
Figure 4–54: United Kingdom – Number of Pregnant Women Vaccinated(Thousand),2010 – 2015
Figure 4–55: United Kingdom – Forecast for Number of Pregnant Women Vaccinated(Thousand),2016 – 2022
Figure 4–56: United Kingdom – Number of Chronic Medical Condition Persons Vaccinated(Thousand),2010 – 2015
Figure 4–57: United Kingdom – Forecast for Number of Chronic Medical Condition Persons Vaccinated(Thousand),2016 – 2022
Figure 4–58: United Kingdom – Number of Healthcare Workers Vaccinated(Thousand),2010 – 2015
Figure 4–59: United Kingdom – Forecast for Number of Healthcare Workers Vaccinated(Thousand),2016 – 2022
Figure 4–60: Spain – Influenza Vaccine Market (Million US$),2010 – 2015
Figure 4–61: Spain – Forecast for Influenza Vaccine Market (Million US$),2016 – 2022
Figure 4–62: Spain – Total Number of Persons Vaccinated(Thousand), 2010 – 2015
Figure 4–63: Spain – Forecast for Total Number of Persons Vaccinated(Thousand), 2016 – 2022
Figure 4–64: Spain – Number of 65+ Years of Age Persons Vaccinated(Thousand),2010 – 2015
Figure 4–65: Spain – Forecast for Number of 65+ Years of Age Persons Vaccinated(Thousand),2016 – 2022
Figure 4–66: Spain – Number of Pregnant Women Vaccinated(Thousand),2010 – 2015
Figure 4–67: Spain – Forecast for Number of Pregnant Women Vaccinated(Thousand),2016 – 2022
Figure 4–68: Spain – Number of Chronic Medical Condition Persons Vaccinated(Thousand),2010 – 2015
Figure 4–69: Spain – Forecast for Number of Chronic Medical Condition Persons Vaccinated(Thousand),2016 – 2022
Figure 4–70: Spain – Number of Healthcare Workers Vaccinated(Thousand),2010 – 2015
Figure 4–71: Spain – Forecast for Number of Healthcare Workers Vaccinated(Thousand),2016 – 2022
Figure 10–1: Sanofi Pasteur – Influenza Vaccine Net Sales (Million US$),2011 – 2015
Figure 10–2: Sanofi Pasteur – Forecast for Influenza Vaccine Net Sales (Million US$),2016 – 2022
Figure 10–3: GSK – Influenza Vaccine Net Sales (Million US$),2011 – 2015
Figure 10–4: GSK – Forecast for Influenza Vaccine Net Sales (Million US$),2016 – 2022
Figure 10–5: AstraZeneca – Influenza Vaccine Net Sales (Million US$),2011 – 2015
